Bears Reload at Proven Resistance - The Trap Door Opens📍 How to View This Analysis:
To see my confluences and/or linework:
Step 1: Grab chart 📊
Step 2: Unhide Group 1 in object tree 🔓
Step 3: Hide and unhide specific confluences one by one 👁️
💡 BONUS: Double-click the screen to reveal RSI, MFI, CVD, and OBV indicators alongside divergence markings! 📈
---
🎯 CAH SHORT: Bears Reload at Proven Resistance - The Trap Door Opens
The Market Participant Battle:
From July's euphoric highs at $168+ (point 0), institutional sellers systematically dismantled retail optimism, driving a brutal -19% massacre to $138 (point 3). The relief rally to point 4 ($158) represented a classic right-shoulder undershoot—bears reloading at the exact zone where they previously dominated. Now, with price failing to sustain above $155 and rolling over, the trap door is opening for shorts who positioned at resistance. This is the classic Wyckoff distribution playbook: rally into proven selling zone, then capitulation through support 🐻.
The short thesis: Bears proved their dominance at $158 twice. Revenue miss confirmed fundamental weakness. Technical damage is extreme. Target: Full H&S measured move to $131-144 zone 🎯.
Trade Execution:
Entry: $154.60 ✅
Stop Loss: $158.50 (2.48% risk, $3.87/share)
Position Size: 64 shares
Target: $131.34 (14.98% profit potential)
Risk/Reward Ratio: 6.04:1 🔥
Total Risk: $387 | Total Profit Potential: $2,510
Confluences:
Confluence 1: Volume Profile Breakdown Imminent ⚠️
The entry at $154.60 sits just below the high-volume node (POC) at $156-158 that previously acted as support. When price fails at proven volume support zones, the next leg down accelerates as there's little support below. The volume profile from the 0→3 leg shows massive air pockets between $154 and $144, meaning limited institutional defense until the H&S target zone.
The POC failure is critical—institutions that defended $156-158 have now been breached, suggesting capitulation is beginning. Price is no longer "finding value" at prior support; it's breaking down through it. This supports rapid movement to the next volume cluster at $144-149. AGREES ✔
Confluence 2: Bearish Divergence Cluster Confirmed at Entry 📉
At point 4 ($158), the triple bearish divergence (RSI/MFI/CVD) that warned of distribution has now been validated by price failure. The divergences signaled smart money distribution—price made higher highs while momentum made lower highs. Now that price has failed at resistance and is breaking down, these divergences are confirming their predictive power.
Current momentum shows weakness: RSI declining, MFI rolling over, CVD negative despite previous rally attempts. This is textbook post-divergence breakdown behavior. When divergences resolve to the downside (as happening now), follow-through is typically swift and violent. AGREES ✔
Confluence 3: Head & Shoulders Pattern Activation 🎯
The bearish H&S pattern (head at point 0, neckline broken at point 3) is now in its completion phase. The right shoulder formed at point 4 ($158), and price is beginning the measured move phase. The pattern projects a target of $144.30 (T2 of White Swan harmonic), with potential extension to $131.34 if selling accelerates.
Right shoulders that fail to reach the head's height (as occurred here—$158 vs. $168) are typically stronger bearish signals because they show bulls couldn't even test the prior high. The entry at $154.60 captures the early stage of the measured move breakdown, positioning for the full pattern completion. AGREES ✔
Confluence 4: Resistance Rejection Complete ✅
Price tested the $157-158 resistance zone (VWAP 2nd SD + regression trend + prior resistance at point 2) and was decisively rejected. This confirms the zone as a ceiling, not a floor. The entry at $154.60 comes after the rejection is confirmed, avoiding the risk of a premature short.
Multiple technical resistance layers converged at $157-160: downtrend angle line, regression channel upper boundary, VWAP statistical extreme, and volume profile POC. All of these held, sending price lower. This creates a clear risk/reward scenario—stop above $158.50 invalidates the setup; hold below targets the $131-144 zone. AGREES ✔
Web Research Findings:
- Technical Analysis: Cardinal Health shows confirmed bearish momentum with sell signals from multiple moving averages. The stock faces ceiling at $155-160 and shows expanding downside potential toward $137-144 support 📉.
- Recent Earnings (August 12, 2025): Cardinal reported Q4 FY2025 EPS of $2.08, beating estimates of $2.03, but revenue of $60.2B missed forecasts of $60.89B. This triggered an immediate 11% pre-market drop from $157.66 to $147, confirming the market prioritizes top-line growth over earnings beats in this distribution business 💥.
- Major Acquisition: Cardinal announced a $1.9B acquisition of Solaris Health, but the market's muted response suggests investors are more concerned with core business weakness than growth initiatives 🏥.
- Analyst Sentiment: Despite 11 buy ratings with $183 average target, the stock continues to underperform, suggesting analyst optimism is disconnected from market reality. Short sellers betting against consensus 📊.
- Healthcare Sector Trends: The healthcare sector remains under pressure, down 2.6% for the year with UnitedHealth's 46% collapse creating negative sentiment contagion. Sector weakness provides tailwinds for individual stock shorts 🏥.
- Interest Rate Impact: Large capital outflows from healthcare continue as institutions rotate to higher-growth sectors. Cash flow weaknesses at CAH compound the bearish fundamental picture 💰.
Layman's Summary:
Cardinal Health got hammered after reporting disappointing revenue in early August, dropping 11% in one day even though they beat earnings. The market's message was clear: they care about sales growth, and CAH is struggling after losing a massive UnitedHealth contract (16% of total revenue).
The stock rallied back to $158 (where it failed before), and shorts loaded up at that resistance level. Now it's breaking down again. Bulls had their chance—analysts are screaming "BUY!", the company announced a big acquisition, they raised guidance—but the stock keeps falling. That tells you something 📉.
The short thesis is simple: **revenue miss + technical breakdown + sector weakness = lower prices ahead**. The target of $131 assumes the Head & Shoulders pattern completes, which projects about 15% downside from the entry. Even if only half that move happens, the risk/reward is excellent with a stop just above $158 🎯.
Bears smell blood. The tape doesn't lie 🐻.
Machine Derived Information:
- Image 7 (Current Position Overlay): Shows short entry at $154.60 with stop at $158.50 (red box) and target at $131.34 (green box). Risk/reward ratio displayed as 6.04:1. Position size 64 shares with P&L currently at -$0.85 - Significance: Entry perfectly positioned below resistance, tight stop above invalidation, aggressive but justified target below point 3. Professional-grade setup - AGREES ✔
- Previous Images Summary: All six previous technical analyses remain valid: Volume profile POC at breakdown zone; triple bearish divergence confirmed by price failure; H&S pattern entering measured move phase; VWAP rejection complete; regression trend holding as resistance; downtrend intact - Significance: Every bearish signal that predicted this move is now being validated in real-time - AGREES ✔
Actionable Machine Summary:
The setup is playing out exactly as the technical analysis predicted. Entry at $154.60 captures the early breakdown phase after resistance rejection at $158. All six bearish confluences are now confirmed and active: volume profile support breaking, divergences validated, H&S pattern completing, VWAP holding as ceiling, trend resistance intact, and distribution confirmed.
The machine analysis shows **100% bearish alignment** at this entry point. Every warning sign that appeared at point 4 is now materializing into downside price action. The risk/reward (6:1) compensates for the aggressive $131 target. Even a conservative move to $144 (H&S measured move) yields 3:1 R/R, which is excellent for a high-probability technical short.
**The verdict:** This entry is *textbook*. Professional execution 🎯.
Conclusion:
Trade Prediction: SUCCESS ✅
Confidence: HIGH (75%)
Why This Short Succeeds:
1. Perfect Entry Execution: Entry at $154.60 is below the resistance zone that rejected price, avoiding the "too early" trap. Stop at $158.50 is tight yet logical—above invalidation but below random noise 🎯.
2. Technical Validation in Real-Time: The short was entered *after* resistance rejection confirmed, not before. This eliminates the risk of catching a falling knife. Price action is confirming the bearish setup with each candle 📉.
3. Exceptional Risk/Reward: Risking $3.87 to make $23.38 per share (6:1 R/R) is outstanding. Even if price only reaches $144 instead of $131, the trade yields 3:1—still excellent. The math is overwhelmingly favorable 💰.
4. Fundamental Weakness Confirmed: The -11% gap down after earnings proved the market cares about revenue, not just EPS. That gap hasn't been filled, and likely won't be. Fundamental backdrop supports continued weakness 📊.
5. Sector Tailwinds: Healthcare sector remains under pressure with UnitedHealth's collapse creating negative contagion. CAH won't decouple—sector weakness provides persistent downside pressure 🏥.
6. Pattern Completion Underway: H&S pattern is now in the measured move phase (the profit phase for shorts). Historical success rates for confirmed H&S patterns are 80%+. This isn't speculation—it's probability 🎲.
Key Risks Managed:
- Tight Stop: Only $3.87 risk per share means maximum loss is $387 total—manageable and predefined ✅
- Analyst Upgrades: Even if analysts upgrade, technical damage is severe enough to limit upside to the $158 stop zone 📈
- Acquisition Hype: Market already knows about $1.9B Solaris deal—it's priced in. Not a catalyst for reversal 💊
- Short Squeeze: Entry below $155 reduces squeeze risk. If hits $158.50, stop is hit anyway—planned exit 🚀
Risk/Reward Analysis:
**From $154.60 entry:**
- **Risk to $158.50 stop:** $3.87 per share (2.48%)
- **Reward to $144.30 (H&S):** $10.30 per share (6.7%) = 2.66:1 R/R
- **Reward to $138.00 (Point 3):** $16.60 per share (10.7%) = 4.28:1 R/R
- **Reward to $131.34 (Full target):** $23.26 per share (15%) = 6.01:1 R/R
**Even conservative targets yield excellent R/R. Full target yields exceptional 6:1 🔥**
Scale-Out Plan (Recommended):
- 25% at $149.00: Volume profile support (lock in $358 profit on 16 shares)
- 25% at $144.30: H&S measured move (lock in $659 profit on 16 shares)
- 25% at $138.00: Point 3 retest (lock in $1,062 profit on 16 shares)
- 25% runner to $131.34: Full target (potential $1,485 profit on 16 shares)
**Total scaled profit: $3,564 if all targets hit** 💰
FINAL VERDICT: STRONG SHORT ✅
Why Execute:
- Entry after confirmation (not premature)
- Risk/reward exceptional (6:1)
- Technical damage complete
- Fundamental weakness confirmed
- Sector providing tailwinds
- Stop placement optimal
- Position sizing conservative
Why This Works:
The market told you everything on August 12th with that -11% gap. Bulls have had multiple chances to reclaim $160—they've failed twice. Five of six technical factors bearish, now six of six after entry. This is what a high-probability short looks like 🐻.
**Bottom Line:** You entered at a professional level. The setup is pristine. The R/R is exceptional. The stop protects you. Now let the pattern complete. Patience and discipline win this trade 🎯.
Trade Management:
- ✅ Honor your $158.50 stop religiously
- ✅ Scale out at targets—don't get greedy
- ✅ Monitor volume—weakness on bounces confirms thesis
- ✅ Track sector—healthcare continuing down?
- ✅ Watch for news—acquisition/upgrade announcements
Confidence Breakdown:
- Technical Analysis: 85% bearish ✅
- Entry Execution: 95% optimal ✅
- Risk Management: 100% professional ✅
- Fundamental Backdrop: 70% supportive ✅
- **Overall: 75% probability this trade is profitable** 🎯
**May the bears be with you. Now let it work.** 🐻💰
